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It has been more than 15 years since the identification of individual interleukin-27 (IL-27) and IL-27 receptor
components. The last decade has seen the description of the signaling pathways engaged by IL-27, and an
appreciation has emerged that this cytokine canmodulate the intensity and duration of many classes of T cell
responses. Here we provide an overview of the immunobiology of IL-27 and review advances in under-
standing the functions of individual IL-27 and IL-27 receptor subunits and the role of IL-27 in dictating the
balance between protective and pathological immunity. Additionally, this cytokine has been proposed as
a therapy tomodify inflammatory conditions or to promote antitumor responses, and situations where exper-
imental and clinical data sets implicate IL-27 in the outcome of disease are highlighted.Introduction
Interleukin-27 (IL-27) is a heterodimeric cytokine composed of
the Epstein-Barr virus-induced gene 3 (EBi3) and IL-27p28,
which engages a receptor composed of gp130 and the IL-
27Ra that activates Janus kinase (JAK)-signal transducer and
activator of transcription (STAT) and mitogen activated protein
kinase (MAPK) signaling (see Figure 1; Kastelein et al., 2007).
Although the Ebi3 subunit and IL-27Ra chain were first described
in 1996 and 1998, respectively, it was not until 2001 that a combi-
nation of in silico and biochemical approaches provided themain
framework for understanding how IL-27 functioned and not until
2004 that the full receptor composition was described (Pflanz
et al., 2002, 2004). There are a number of structural motifs that
characterize the IL-27 receptor and subunits that highlight its
evolutionary relationship with IL-6, IL-12, and IL-23 and which
help explain their use of similar signaling pathways and overlap-
ping activities (Kastelein et al., 2007). These latter cytokines have
emerged as critical determinants in the development of T helper
1 (Th1) and Th17 cell responses and represent major targets for
drug development to manage inflammatory conditions associ-
ated with aberrant T cell responses. Because IL-27 is a member
of this family and utilizes JAK-STAT signaling associated with
T cell activation, when this cytokine was first described there
was an expectation that it would be proinflammatory. This notion
was reinforced by reports on mice that lacked the IL-27Ra and
in vitro studies that emphasized the ability of IL-27 to promote
NK and T cell proliferation and production of IFN-g (Chen
et al., 2000; Pflanz et al., 2002; Yoshida et al., 2001). However,
when Il27ra/ mice were challenged with a number of patho-
gens or utilized in a variety of autoimmune models, the data
sets that emerged suggested that one of the main functions of
IL-27 in these settings was to limit the intensity and duration of
T cell responses (Artis et al., 2004a, 2004b; Batten et al., 2006;
Hamano et al., 2003; Ho¨lscher et al., 2005; Miyazaki et al.,
2005; Stumhofer et al., 2006; Villarino et al., 2003). Since then,
multiple studies have addressed the basis for the inhibitory
effects of IL-27 on Th1, Th2, and Th17 cell responses and high-960 Immunity 37, December 14, 2012 ª2012 Elsevier Inc.lighted the many mechanisms engaged by this cytokine (see
Figure 2). This includes the ability to antagonize T cell production
of IL-2, a direct inhibitory effect on Th2 and Th17 cell activities,
and the fact that IL-27 is a major stimulus for T cell production
of IL-10. There is now an acceptance that IL-27 can limit many
facets of T cell-mediated pathology but also research indicating
that it can promote Th1 cell type responses (Cao et al., 2008;
Mayer et al., 2008). Nevertheless, ongoing studies continue to
identify novel suppressive functions of IL-27 and there has
been progress in translating the basic findings from murine
models into clinical settings. Here we highlight recent advances,
frame newer questions that have arisen about this cytokine, and
provide an overview of the current knowledge of the immunobi-
ology of IL-27 that may inform the development of therapies to
limit or enhance immune responses.
Promiscuity of IL-27 and IL-27 Receptor Subunits
Interleukin-12 remains the prototypic heterodimeric cytokine
and the association of the IL-12p35 and IL-12p40 subunits is
dependent on disulphide interactions. In contrast, the nature of
the association between IL-27p28 and EBi3 is uncertain and
these subunits can be secreted independently and are differen-
tially expressed in various cell types (Pflanz et al., 2002). These
observations imply that IL-27p28 and EBi3 might associate
with other factors to form novel cytokines or have biological
functions of their own. Evidence also exists indicating that
EBi3 can partner with IL-12p35 to form IL-35, which has been
linked to the activities of regulatory T cells, and the biology of
this cytokine is reviewed in detail elsewhere (Vignali and Kuch-
roo, 2012). Similarly, the IL-27p28 subunit can bind to cyto-
kine-like factor 1 (CLF), and this heterodimer promotes T and
NK cell production of cytokines (Crabe´ et al., 2009). This inherent
combinatorial biology lends itself to the generation of designer
cytokines and although there is currently no evidence that
IL-27p28 and IL-12p40 can combine naturally, this recombinant
hematopoetin can suppress inflammation in a model of experi-
mental autoimmune uveitis (EAU) associated with the inhibition
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Figure 1. Impact of IL-27 on Lymphocyte Signaling Pathways
Dimerization of gp130 and IL-27Ra engages JAK1, JAK2, and Tyk2 that
engage the MAPK pathway and activation of multiple STATs, most notably
STAT1 and STAT3. The activation of STAT1 is linked to inhibition of GATA-3
and RoRgt but upregulation of PD-L1, T-bet, and IL-10. The ability to engage
STAT3 is linked to increased proliferation as well as IL-10 whereas the MAPK
pathway intersects with AHR to promote IL-10 and IL-21.
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(Wang et al., 2012). The initial observation that IL-27p28 alone
had a modest ability to antagonize Th17 cell responses
(Stumhofer et al., 2006) foreshadowed reports that overexpres-
sion of IL-27p28 can have quite profound biological effects.
The generation of a variant of IL-27, in which the IL-27p28
subunit could not interact with gp130, revealed that this mutant
acted as a receptor antagonist and limited liver damage medi-
ated by Th1 cells (Rousseau et al., 2010). Indeed, IL-27p28 can
be secreted independently of EBi3 and, consistent with struc-
tural predictions that IL-27p28 would bind to the type I domain
of gp130, this subunit can block the activity of cytokines (IL-6,
IL-11, and IL-27) that utilize this portion of gp130 to signal (Pflanz
et al., 2004; Stumhofer et al., 2010). The physiological relevance
of these observations was illustrated by the finding that overex-
pression of IL-27p28 antagonizes gp130-dependent B cell
responses (Stumhofer et al., 2010), can block liver damage (Di-
bra et al., 2012), abrogates antitumor responses and suppresses
graft rejection (Shimozato et al., 2009), and blocks EAU (Wang
et al., 2012). Together, these results have led to the idea that
IL-27p28 can act as a naturally occurring low-affinity antagonist
of signaling through the gp130 receptor that is reminiscent of
mechanisms that limit IL-1 activity (Stumhofer et al., 2010).
Although initial studies that utilized overexpression approaches
were key to identifying the pairing of IL-27p28 and EBi3, a major
knowledge gap remains in understanding the factors that govern
whether IL-27p28 is secreted alone or as a heterodimer, how
these components dimerize, and whether there are differences
between murine and human cells. Based largely on the overex-
pression data in HEK293T cells, the current paradigm has human
EBi3 secreted in excess, whereas human IL-27p28 can besecreted only when coexpressed with EBi3 (Pflanz et al.,
2002). In the mouse, the opposite is true: IL-27p28 is secreted
in excess whereas EBi3 can be secreted only when coexpressed
with IL-27p28 (Pflanz et al., 2002). It is pertinent to acknowledge
the current limitations with the commercial reagents to reliably
measure the IL-27 heterodimer in human and mouse systems
and to distinguish IL-27p28 alone or as part of IL-27. This
becomes important if there are efforts to develop IL-27p28 clin-
ically and there needs to be caution in extrapolating the functions
of IL-27p28 in mice to the human situation.
Given the close relationship between IL-6, IL-12, and IL-27,
the advanced state of knowledge of how IL-6 and IL-12 interact
with their receptor components has informed many aspects of
IL-27 signaling. Thus, the observation that the gp130 subunit is
utilized by a group of related cytokines, including IL-6 and
IL-27, whereas IL-12Rb1 is employed by IL-12 and IL-23, raises
questions about whether the IL-27Ra chain can function as
a receptor for other cytokines. Indeed, IL-27Ra is a component
of the receptor (that includes gp130 and IL-6Ra) for the p28-
CLF heterodimer (Crabe´ et al., 2009), and the neuroprotective
peptide Humanin also utilizes IL-27Ra (Hashimoto et al., 2009).
There is also evidence that IL-27Ra can form homodimers that
activate the JAK-STAT pathway that can promote transforma-
tion of hematopetic cells (Pradhan et al., 2007). One additional
facet of IL-6 biology that is relevant to IL-27 is the ability of
IL-6 to pair with soluble IL-6Ra. This IL-6-IL-6Ra complex is
able to bind to gp130 alone and transduce signaling in a process
known as trans signaling (Rose-John et al., 2006). This process is
thought to underlie the evolution of IL-27 because EBi3, which is
analogous to the soluble IL-6Ra receptor, binds to IL-27p28,
which is structurally similar to IL-6. At this point, there is no
evidence that IL-27 employs trans signaling, but if IL-27 can be
engineered to take advantage of this type of biology, it would
profoundly alter current perspectives on the cell types that can
be targeted by IL-27. Additional structure-function studies would
be required to inform the development of altered versions of IL-
27 that could act as receptor agonists or antagonists. Regard-
less, the increased understanding of the use and reuse of the
IL-27 cytokine and receptor components has already compli-
cated the interpretation of studies with Ebi3/ and Il27ra/
animals, and the physiological significance of other complexes
that contain elements of the IL-27-IL-27R cassette requires
further study.
lL-27 Regulating Regulatory Pathways
Although the IL-27Ra chain and IL-27 were initially linked to the
development of Th1 cell responses, there was a gradual transi-
tion to the recognition that this factor acts as a suppressor of
many T cell subsets (Kastelein et al., 2007). With that realization,
understanding how IL-27 could dampenmultiple types of inflam-
mation became a major question (see Figure 2) and the ability of
IL-27 to antagonize the production of IL-2 may help to explain
some of its broad suppressive effects (Villarino et al., 2006).
With the identification of ‘‘master regulators’’ of T helper cell
subsets, the observation that IL-27 reduced basal GATA3
expression provided an insight into the mechanism used to limit
Th2 cell development (Lucas et al., 2003). Data that IL-27
blocked expression of RoRgt explains the antagonistic effects
of IL-27 on the production of IL-17 (Diveu et al., 2009). GivenImmunity 37, December 14, 2012 ª2012 Elsevier Inc. 961
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Figure 2. Key Regulatory Effects of IL-27 on T and B Cells
The proinflammatory properties attributed to IL-27 include the development of CTL, the promotion of Tfh cells, and a direct ability to promote B cell production of
antibodies. The regulatory activities of IL-27 include the ability to promote expression of the inhibitory receptor PD-L1 and IL-10 production by multiple helper
T cells. The ability to generate a CXCR3+ Treg cell population is specialized to operate at sites of Th1 cell inflammation whereas the ability to control Th2 and Th17
cell inflammation is due to direct inhibitory effects on GATA3 and RoRgt.
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2003), a transcriptional response associated with Th1 cell
activity, the molecular and cellular basis for the enhanced Th1
cell responses observed in the absence of IL-27 in vivo has
been more difficult to comprehend. Nevertheless, advances
have been made over the last 5 years that described the ability
of IL-27 to promote a series of regulatory pathways that appear
secondary to Th1 cell development andwhich prevent protective
responses from becoming pathological.
IL-27 and the Production of IL-10
The primary studies that showed that IL-27Ra-deficient mice in-
fected with intracellular parasites developed a lethal inflamma-
tory response mediated by CD4+ T cells was reminiscent of
work demonstrating that Il10/ mice challenged with the
same organisms developed similar immune pathology (Gazzi-
nelli et al., 1996; Hamano et al., 2003; Hunter et al., 1997; Villarino
et al., 2003). However, in the Il27ra/ mice, global defects in
IL-10 production during the acute phase of these infections
were not readily apparent, and these mice do not develop spon-
taneous colitis or display overt susceptibility to cancer, charac-
teristic of the absence of IL-10 (Berg et al., 1996). These initial
reports were interpreted as showing that IL-10 and IL-27 acted
in distinct fashions and were consistent with a paradigm that
IL-10 mediates its suppressive activities largely through its
effects on accessory cell function whereas IL-27 could directly
inhibit T cells. However, in 2007, a series of studies highlighted
that Th1, Th2, Th17, and Tr1 cell subsets could be activated by
IL-27 to promote the production of IL-10 in the context of infec-
tious and autoimmune conditions and provided an unprece-
dented insight into the heterogeneity that can be apparent
even within T cell responses that are defined by current T helper
cell subset nomenclature (Awasthi et al., 2007; Fitzgerald et al.,
2007b; Stumhofer et al., 2007). This phenomenon has been
confirmed in a variety of other experimental models and
expanded to humans (Anderson et al., 2009; Ansari et al.,
2011; Batten et al., 2008; Freitas do Rosa´rio et al., 2012; Muru-
gaiyan et al., 2009; Perona-Wright et al., 2012; Sun et al.,
2011; Wang et al., 2011). Whereas initial reports defining
the molecular basis for these events identified the involvement
of STAT1 and STAT3 signaling (Stumhofer et al., 2007) and of962 Immunity 37, December 14, 2012 ª2012 Elsevier Inc.the inducible costimulator (ICOS) (Pot et al., 2009), the complex
molecular events that underpin IL-10 production in T cells are
still emerging (see Figure 1). For example, the ability of IL-27
to activate MAPK signaling and to induce expression of the
AP-1 transcription factor promotes production of IL-21 that
sustains IL-10 expression (Pot et al., 2009; Xu et al., 2009).
Furthermore, the aryl hydrocarbon receptor and its ability to
partner with c-Maf to optimize interactions with the Il10 and
Il21 promoters has been implicated in these events (Apetoh
et al., 2010). Much of this more recent work has been framed
in the context of Tr1 cells, but because IL-10 can be produced
by all T cell subsets, it seems likely that these principles for the
control of IL-10 will be broadly relevant. However, it should be
noted that whereas IL-27 promotes the production of IL-10 by
effector CD8+ T cells during viral infections, memory CD8+ cells
lose expression of gp130 and are nonresponsive to IL-27 (Per-
ona-Wright et al., 2012). It has been proposed that this allows
these memory populations to provide better secondary
responses and illustrates a mechanism to limit the inhibitory
effects of IL-27.
IL-27 and PD-L1
IL-27’s promotion of IL-10 is one mechanism to limit inflamma-
tory responses, but there are regulatory networks mediated by
other cytokines and receptor-ligand interactions that limit
different facets of an immune response. The PD-1-PD-L1 inter-
action has emerged as a major mediator of exhaustion in
T cells, most prominently in the setting of chronic viral infections
and cancer (Barber et al., 2006; Topalian et al., 2012), and so
studies in which microarray analysis of CD4+ T cells identified
PD-L1 as a target of IL-27 provide an important link between
two apparently distinct regulatory mechanisms. There are
reports in which IL-27 was shown to inhibit the development of
Th17 cells but had less of an effect on established responses
(El-behi et al., 2009), but the ability of IL-27 to promote PD-L1
by CD4+ T cells allows these cells to act in trans to limit Th17
cell responses and ameliorate the development of EAE, thus
providing another strategy for IL-27 to indirectly limit inflamma-
tion mediated by Th17 cells (Hirahara et al., 2012). Given the
prominent role of PD-1-PD-L1 in viral infections and T cell
exhaustion, these studies also highlight the gap in our
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nity and provide the impetus to determine whether this cytokine
is involved in coordinating the expression of other inhibitory
pathways associated with exhaustion.
IL-27 and Treg Cells
A major paradox for the last 5 years has been the disparate find-
ings on IL-27: that it can limit inflammation and that it antago-
nizes Treg cell development or conversion, a major arm of the
immune system devoted to operational tolerance. Several
groups have observed that IL-27 antagonizes the ability of
TGF-b and IL-2 to generate inducible Treg cells (Huber et al.,
2008;Neufert et al., 2007; Stumhofer et al., 2007) and in a transfer
model of colitis, the absence of the IL-27Ra led to increased
conversion of Treg cells and this population ameliorated disease
more efficiently than did wild-type cells (Cox et al., 2010). More-
over, mice transgenically overexpressing IL-27 lack Treg cell
populations and develop an autoimmune disease analogous to
the scurfy disease present in mice that lack Foxp3 (Wojno
et al., 2011). Taken together, these findings would be interpreted
as showing that IL-27 negatively impacts Treg cell homeostasis.
However, in the transgenic model, the loss of Treg cells appears
to be secondary to the ability of IL-27 to limit the production of
IL-2, which is required to maintain Treg cell populations. More-
over, Il27ra/ mice have normal Treg cell frequencies; IL-27
does not downregulate Foxp3 expression nor does it antagonize
the ability of Treg cells to function in suppression assays (Cox
et al., 2010; Villarino et al., 2005); and more recent studies
have found that IL-27 promotes Treg cell growth and survival
(Hall et al., 2012).
These contradictory reports on effects of IL-27 on Treg cells
stress that the heightened production of IL-2 observed in the
absence of IL-27 signaling can complicate the interpretation of
these studies. An alternative view on the interaction of IL-27
and Treg cells began to emerge with reports in 2009 that during
Th1 cell responses to the intracellular pathogens Mycobacteria
or Toxoplasma gondii, a population of T-bet+ Treg cells emerged
that could also produce IFN-g (Koch et al., 2009; Oldenhove
et al., 2009). During mycobacterial challenge, the development
of this population was dependent on Treg cell expression of
STAT1 that induced T-bet-mediated expression of CXCR3
(Koch et al., 2009). The model that emerged from these latter
studies was that this Th1 cell-like subset of Treg cells developed
in response to IFN-g signals and was specialized to control Th1
cell responses. A role for IL-27 in these events was established
when it was shown that IL-27 can engage this same STAT1-T-
bet transcriptional pathway in Treg cells and that after challenge
with T. gondii, L. major, or Salmonella, IL-27 is required for the
emergence of a T-bet+CXCR3+ Treg cell population at local sites
of inflammation, which produce IL-10 and suppress parasite-
specific effector response (Hall et al., 2012). This led to amodified
model in which the production of IFN-g and IL-27 in distinct
anatomical locations can drive subpopulations of Treg cells to
express CXCR3, which allows these populations to operate at
distinct sites of Th1 cell inflammation. These findings raise new
questions about the precise impact of CXCR3 on Treg cell func-
tion and, when combined with reports that IL-27 upregulates
cellular expression of LFA-1, ICAM-1, and sphingosine 1 phos-
phate (Liao et al., 2007; Owaki et al., 2006), suggest the needfor additional studies to understand the impact of IL-27 on traf-
ficking and behavior of different lymphocytes.
Translating Models to Clinical Disease
With data sets emerging that IL-27 suppresses human Th17 cell
responses and promotes the production of IL-10 (Amadi-Obi
et al., 2007; Apetoh et al., 2010; Murugaiyan et al., 2009), several
groups have already proposed that these properties of IL-27may
be useful therapeutically and there are multiple proof-of-prin-
ciple studies in murine models that support this idea. The oppor-
tunity to apply this information to human disease is invariably
complicated by data sets in which the pro- and anti-inflamma-
tory properties of IL-27 are debated and by questions about
how to interpret aberrant IL-27 levels in different disease states.
IL-27 and Infectious Disease
Parasitic organisms have provided some of the strongest pheno-
types for IL-27 in murine systems; there are now reports in which
IL-27 is linked to the outcome of these infections in humans. For
example, Il27ra/ mice challenged with visceral leishmaniasis
develop enhanced immune pathology (Rosas et al., 2006) and
in patients with visceral disease, serum titers of IL-27 are
elevated and have been linked to the production of IL-10 that
may provide a feedback loop that limits inflammation but allows
parasite persistence (Ansari et al., 2011). In different murine
models of malaria, endogenous IL-27 promotes IL-10, limits
T cell responses, and prevents immune pathology (Findlay
et al., 2010; Freitas do Rosa´rio et al., 2012). In the human setting,
those patients with the most severe clinical malaria have
reduced amounts of IL-27, consistent with the elevated inflam-
matory responses (Ayimba et al., 2011). In contrast, very little
is known about the impact of IL-27 onmodels of fungal infection.
However, in elegant bedside-to-bench studies, Casanova and
colleagues characterized a group of patients with gain-of-func-
tion mutations in STAT1 that were susceptible to mucocuta-
neous candidiasis (Liu et al., 2011). Because IL-17F and
IL-17RA are required for resistance to Candida, one explanation
for this increased susceptibility of these patients is provided by
the enhanced ability of IL-27 and type I IFNs to activate STAT1
and to suppress Th17 cell responses in these patients (Liu
et al., 2011). These results suggest that reduced production of
IL-27 may improve control of fungal organisms, whereas exces-
sive IL-27 activity would promote susceptibility, an idea that has
yet to be tested in murine systems.
IL-27 and Cancer
IL-27 can also act as a potent stimulus for lymphocyte expansion
and survival and there are reports that address the impact of IL-
27 on hematopoesis (Seita et al., 2008) and proliferation (Charlot-
Rabiega et al., 2011). As for many growth factors, IL-27 has also
been linked to tumor progression, and in human patients with
acute myeloid leukemia (AML), the ability of the IL-27Ra to
dimerize has been linked to transformation (Pradhan et al.,
2007). However, IL-27 can have a direct inhibitory effect on
tumor cells, even in the context of AML (Ho et al., 2009; Zorzoli
et al., 2012). Thus, the role of IL-27Ra in cancer biology is
complex, with a well-developed literature that implicates IL-27
in the regulation of antitumor immunity mediated by CD8+
T cells (Chiyo et al., 2005; Hisada et al., 2004; Salcedo et al.,Immunity 37, December 14, 2012 ª2012 Elsevier Inc. 963
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scriptional response reminiscent of Th1 cells, the ectopic
expression of IL-27 promoted antitumor cytotoxic T lymphocyte
(CTL) responses in mice associated with increased proliferation,
expression of T-bet and IL-12Rb2, and production of IFN-g (Sal-
cedo et al., 2009). In that context, there is an increasing appreci-
ation of the role of the PD-1-PD-L1 interaction in cancer and the
observation that IL-27 induces PD-L1 (Hirahara et al., 2012)
implies that IL-27 may be an important molecule in controlling
immune checkpoint mechanisms that operate in cancer. The
IL-27Ra chain is also expressed by epithelial tumor lines (Dibra
et al., 2009) where IL-27 has been linked to promoting expres-
sion of MHC class I-related chain A (MICA), a ligand for
NKG2D, which is an activating receptor expressed on NK and
some CD8+ T cells, that promotes cytotoxicity (Dibra et al.,
2009). Taken together, these findings make it difficult to interpret
how a polymorphism in IL-27p28 that is associated with colo-
rectal cancer (Huang et al., 2012) can impact tumor formation
or surveillance. Given the contributory role of inflammation to
the development of cancer, and in particular the links to the IL-
23-Th17 cell axis (Langowski et al., 2006), it seems likely that
IL-27 would have some impact on the immunological processes
that contribute to these events, but there is a paucity of studies
that address the impact of endogenous IL-27 on tumorogenesis.
IL-27 at Barrier Surfaces: Colitis, Asthma, and Psoriasis
Maladaptive Th2 and Th17 cell inflammatory responses are
characteristic of several diseases (including asthma, colitis,
and psoriasis) that affect barrier sites. These are spectral condi-
tions and grouping them together represents a gross simplifica-
tion that ignores their complex relationship to conditions like
lupus, ankylosing spondylitis, and arthritis. In the setting of
human psoriasis, IL-27 has been associated with promoting
disease (Kanda and Watanabe, 2008; Shibata et al., 2010,
2012), although studies that link IL-27 to keratinocyte and intes-
tinal epithelial cell biology may alter how we view IL-27 acting at
this local barrier site (Diegelmann et al., 2011; Kanda and Wata-
nabe, 2008). Nevertheless, IL-27 represents an attractive candi-
date for a therapeutic approach to manage some of these
diseases. In murine models of asthma, the absence of the IL-
27Ra results in exacerbated lung pathology, characterized by
goblet cell hyperplasia, infiltration of eosinophils, elevated serum
IgE titers, and airway hyperresponsiveness (Miyazaki et al.,
2005; Yoshimoto et al., 2007). Similarly, IL-27Ra-deficient mice
treated with a high dose of DSS develop more severe colitis
associated with elevated Th17 cell activity (Troy et al., 2009),
and in a TNBS model of acute colitis, treatment with IL-27 can
ameliorate disease (Sasaoka et al., 2011). However, there is
a paradox that when low doses of DSS have been used to induce
colitis, IL-27 is thought to contribute to the development of
disease (Honda et al., 2005). An alternative way to consider
some of these findings is that the production of IL-17 is not solely
pathogenic and has a role in promoting barrier function and
limiting tissue damage (Esplugues et al., 2011; Kinugasa et al.,
2000; O’Connor et al., 2009; Ogawa et al., 2004). Indeed, at
low doses of DSS, IL-17 plays a role in protecting from disease
(Ogawa et al., 2004) and in this type of situation the well-charac-
terized ability of IL-27 to antagonize IL-17 production could
explain its proinflammatory activities.964 Immunity 37, December 14, 2012 ª2012 Elsevier Inc.Recognizing that the interpretation of the biological properties
of IL-27 will be context dependent, a series of studies have
emerged in the last 5 years that have highlighted polymorphisms
in IL-27p28 that are connected with these conditions in humans.
One of the first SNPs identified in IL-27p28 that was associated
with disease was linked with susceptibility to asthma and
increased IgE and eosinophilia (Chae et al., 2007) and similar
linkages are reported for polymorphisms in IL-27p28 in chronic
obstructive pulmonary disease (COPD) and IBD (Huang et al.,
2008; Li et al., 2009). Perhaps the most comprehensive study
surveyed a pediatric cohort, utilizing genome-wide association
studies and high-density SNP analysis, and identified IL-27p28
as a candidate gene for Crohn’s disease susceptibility (Imielinski
et al., 2009). Data were presented that suggested that this was
a consequence of reduced IL-27 production and was consistent
with the idea that IL-27 (or IL-27p28)may play a role in preventing
disease. These are all intriguing studies and suggest that
IL-27p28 may be useful as a biomarker or (in a select group of
patients) may be useful as a therapy, analogous to the use of
the IL-1 receptor antagonist.
IL-27 and Multiple Sclerosis
In murine models of MS, early studies showed that treatment
with IL-27 could delay the onset of experimental allergic ence-
phalmyelitis (EAE) and ameliorate established CNS disease,
and in certain models of EAE, the absence of the IL-27Ra results
in more severe disease (Batten et al., 2006; Fitzgerald et al.,
2007a, 2007b). Since then, a series of studies have provided
a link between type I IFNs and IL-27 that may be clinically rele-
vant. The first suggestion that these two cytokines were linked
in MS was the realization that type I IFNs, which are used to treat
MS, were potent inducers of IL-27 (Molle et al., 2007; Pirhonen
et al., 2007). Studies from different groups then linked the ability
of type I interferons to block disease in EAE to their ability to
promote IL-27 (Guo et al., 2008; Shinohara et al., 2008). A clinical
correlate of this finding was provided by a report that in patients
with MS, the ability to produce IL-27 in response to type I inter-
ferons predicts the efficacy of interferon therapy (Sweeney
et al., 2011). Together, these findings suggest that the clinical
efficacy of IFN-b in patients with MS may be attributed to its
ability to induce IL-27 (or the IL-27p28 monomer) and it has
been proposed that IL-27 may represent an alternative strategy
to manage this condition.
IL-27 and the Regulation of Humoral Responses in
Arthritis and Lupus
Systemic lupus erythematosus (SLE) and arthritis are complex
spectral diseases associated with the development of autoanti-
bodies that include pathognomonic levels of anti-dsDNA and
rheumatoid factor, respectively. In the clinical setting, increased
levels of IL-27 have been observed in the synovial fluid of
rheumatoid arthritis patients, which correlates with reduced
local levels of IL-17 and IL-6, consistent with the inhibitory
properties of IL-27 (Niedbala et al., 2008; Tanida et al., 2011).
There are a plethora of models that reflect different facets of
these clinical entities, and some of the earliest studies that
showed that treatment with IL-27 can attenuate disease were
performed in collagen-induced arthritis (Niedbala et al., 2008;
Pickens et al., 2011). In contrast, during proteogylcan-induced
Immunity
Reviewarthritis, endogenous IL-27 appears to promote disease (Cao
et al., 2008).
In MRL/lpr mice, which exhibit a spontaneous disease similar
to SLE, overexpression of the IL-27Ra results in decreased titers
of self-reactive antibody and reduced skin disease (Kido et al.,
2011; Sugiyama et al., 2008), probably a consequence of
increased IL-27 signals. Further support for the idea that IL-27
affects autoantibody responses is found in studies in which dele-
tion of EBi3 in MRL/lpr mice resulted in increased titers of auto-
antibodies but surprisingly improved disease scores (Igawa
et al., 2009). The report that there is a strong inverse correlation
between serum amounts of IL-27 and active disease in SLE
patients (Li et al., 2010) has led to speculation that reduced
IL-27 in some lupus patients can allow for the emergence of
pathological T and B cell responses. One paradox with these
findings is that SLE is associated with high amounts of type I
interferons, which are known to promote IL-27 (Pirhonen et al.,
2007; Remoli et al., 2007; Sweeney et al., 2011). Thus, it is
unclear why lupus patients exhibit lower amounts of IL-27 (Li
et al., 2010). Of course, the inherent heterogeneity that is
apparent in this disease setting may mask direct associations
between relative levels of IL-27 and the type I IFNs.
Given the critical role of antibodies in these disease states,
there has been a focus on understanding the contribution of
Tfh cells to the development of autoantibody responses and
IL-17 has been linked to these events (Doreau et al., 2009).
The effects of IL-27 in this area have been understudied, but
IL-27 can activate c-Maf signaling and upregulate IL-21 and
these events are considered critical for Tfh cell responses
(Bauquet et al., 2009; Nurieva et al., 2008; Pot et al., 2009).
Indeed, culturing CD4+ T cells with IL-27 led to production
IL-21, and vaccination of Il27ra/ mice revealed that they had
impaired IL-21 levels, decreased numbers of Tfh cells, and
reduced production of high-affinity class-switched antibody
(Batten et al., 2010). It should be noted that IL-27 signaling
is not required for the generation of antibody responses in
models of infection, allergy, and autoimmunity (Artis et al.,
2004a; Miyazaki et al., 2005; Shimizu et al., 2005; Yoshida
et al., 2001) and that IL-27 also has direct stimulatory effects
on human B cells (Larousserie et al., 2006; Yoshimoto et al.,
2004) and can directly inhibit the growth of leukemic B cells
(Canale et al., 2011). Understanding the context of when IL-27
promotes or limits humoral responses remains an important
area of investigation.
Concluding Remarks and Future Directions
One of the challenges that the field now faces is to determine
whether manipulation of IL-27 could be used therapeutically to
modulate inflammation that occurs during various human
disease states. The difficulty in this area is making decisions
about which diseases to target and the type of intervention
that would be most appropriate. This could be in a direct fashion
by using agonists of the IL-27R or by an indirect strategy, as sug-
gested by studies showing that the ability of probiotic bacteria to
induce IL-10, which can ameliorate experimental colitis, is
dependent on IL-27 (Jeon et al., 2012). There may also be situa-
tions where the blockade of IL-27 would prove beneficial, and
appreciating how the role of IL-27 is likely to vary depending
on the underlying disease cause will be important. Many of thehuman studies described above are informative in thinking about
how the immunobiology of IL-27 may be translated, but ques-
tions remain about how individual polymorphisms might impact
the expression patterns of IL-27. Intriguingly, all of the polymor-
phisms reported to date have been associated with IL-27p28
and it is unclear whether this represents effects on the cytokine
IL-27 and/or the ability of the IL-27p28 subunit to act as a
receptor antagonist. Regardless, clinical studies have emerged,
such as those with patients that express gain-of-function
mutations of STAT1, that highlight the ability of IL-27 to suppress
Th17 cells in humans (Liu et al., 2011). Another area in which
further insights into the significance of IL-27 in humans may be
gained are the clinical trials that target the Janus kinases
(JAK), which mediate the effects of IL-6, IL-12, and IL-23.
Currently, JAK inhibitors that have been designed to target
inflammatory pathways mediated by these latter cytokines are
in clinical trials for arthritis and lupus. These inhibitors should
also affect the JAKS utilized by IL-27 (as well as IL-10 and type
I IFNs), and it is possible that treatment with these compounds
may lead to dysregulation of the natural regulatory networks
that limit inflammation. A lack of adverse inflammatory events
would suggest that the endogenous regulatory pathways
provided by IL-27 represent secondary responses to ongoing
inflammation rather than mechanisms that continuously enforce
operational tolerance.
The prior 10 years have seen an evolution of our understanding
of IL-27: from acting as a driver of Th1 cell responses, to the
broad inhibitory effects of IL-27, to a realization that this is
a factor that engages multiple lymphocyte populations to partic-
ipate in a program of diverse regulatory mechanisms that are
responsible for returning the immune response to homeostasis.
From a signaling perspective, the growing appreciation of the
distinct biological properties of IL-6, IL-12, IL-23, and IL-27 rai-
ses basic questions about how similar downstream signals are
integrated to provide functionally disparate transcriptional
programs. This is a question relevant to many biological systems
and the fact that IL-6 and IL-27 both prominently activate STAT1
and STAT3 but have profoundly different effects on Th17 and
Treg cells provides a system to dissect how apparently similar
signals provide distinct functions. The more recent studies that
have linked IL-27 to the production of IL-10, the activation
of Treg cells, and expression of PD-L1 highlight our lack of
knowledge about how the suppressive activities of IL-27 are
coordinated. These pathways may be redundant, may act inde-
pendently, or may represent complementary cassettes that are
coordinated in a parallel or linear fashion. Understanding the
underlying biology of IL-27 can provide a template to understand
how the immune system approaches the problem of tempering
appropriate and aberrant responses.ACKNOWLEDGMENTS
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